Subcutaneous Epcoritamab in Combination with Rituximab plus Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

被引：11

作者：

Falchi, Lorenzo ^{[1
]}

Leslie, Lori A. ^{[2
]}

Belada, David ^{[3
]}

Kopeckova, Katerina ^{[4
]}

Offner, Fritz ^{[5
]}

Brody, Joshua ^{[6
]}

Canales, Miguel ^{[7
]}

Martin Garcia-Sancho, Alejandro ^{[8
]}

Nijland, Marcel ^{[9
,10
]}

Andersson, P-O ^{[11
]}

Awan, Farrukh T. ^{[12
]}

Christensen, Jacob Haaber ^{[13
]}

Drott, Kristina ^{[14
]}

Hellstrom, Mats ^{[15
]}

Lewerin, Catharina ^{[16
]}

Narkhede, Mayur ^{[17
]}

Snauwaert, Sylvia ^{[18
]}

Wahlin, Bjorn E. ^{[19
]}

Rana, Ali ^{[20
]}

Abbas, Aqeel ^{[20
]}

Wang, Liwei ^{[20
]}

Minh Dinh ^{[21
]}

Vermaat, Joost S. P. ^{[22
]}

Abrisqueta, Pau ^{[23
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA

[2] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[3] Charles Univ Prague, Hosp & Fac Med, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[4] Fak Nemocnice Motole, Prague, Czech Republic

[5] Univ Ziekenhuis Gent, Ghent, Belgium

[6] Icahn Sch Med Mt Sinai, New York, NY USA

[7] Hosp Univ La Paz, Madrid, Spain

[8] Hosp Univ Salamanca, Salamanca, Spain

[9] Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

[10] Univ Groningen, Groningen, Netherlands

[11] Sodra Alvsborgs Sjukhus, Boras, Sweden

[12] Univ Texas Southwestern Med Ctr, Dallas, TX USA

[13] Odense Univ Hosp, Odense, Denmark

[14] Skane Univ Hosp, Lund, Sweden

[15] Uppsala Univ Hosp, Uppsala, Sweden

[16] Sahlgrens Univ Hosp, Gothenburg, Sweden

[17] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[18] AZ Sint Jan Brugge, Dept Hematol, Brugge, Belgium

[19] Karolinska Inst, Stockholm, Sweden

[20] Genmab, Princeton, NJ USA

[21] AbbVie Inc, N Chicago, IL USA

[22] Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands

[23] Hosp Univ Vall dHebron, Barcelona, Spain

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158232

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1471 / 1473

页数：3

共 50 条

[21] RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.
Fowler, Nathan Hale
Morschhauser, Franck
Feugier, Pierre
Bouabdallah, Reda
Tilly, Herve
Palomba, Maria Lia
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[22] PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS
Burke, J. M.
Andorsky, D. J.
Yacoub, A.
Melear, J.
Coleman, M.
Kolibaba, K.
Brooks, H.
Bitran, J.
Fanning, S.
Lansigan, F.
Ricker, J. L.
Foon, K.
Llorente, M.
Li, J.
Sharman, J.
HAEMATOLOGICA, 2017, 102 : 249 - 250
[23] A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL).
Olszewski, Adam J.
Huntington, Scott F.
Ollila, Thomas
Pelcovits, Ari
McMahon, Jessica B.
Yakirevich, Inna
Sturtevant, Ashlee
Chorzalska, Anna
Morgan, John
Dubielecka, Patrycja
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[24] Combination of Ibrutinib with Rituximab Versus Placebo with Rituximab for First-Line Treatment of Follicular Lymphoma: PERSPECTIVE, a Randomized Phase 3 Study
Flinn, Ian
Gordon, Leo
Rule, Simon
Chen, Robert
Kwei, Long
Chu, Alvina D.
Fowler, Nathan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S277 - S278
[25] First-Line Treatment With Subcutaneous Epcoritamab plus R-CHOP in Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Phase 1/2 Data Update
Falchi, Lorenzo
Offner, Fritz
Belada, David
Brody, Joshua
Linton, Kim M.
Karimi, Yasmin
Cordoba, Raul
Snauwaert, Sylvia
Abbas, Aqeel
Wang, Liwei
Wu, Jun
Elliott, Brian
Clausen, Michael Roost
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S380 - S380
[26] Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
Davies, Andrew
Merli, Francesco
Mihaljevic, Biljana
Mercadal, Santiago
Siritanaratkul, Noppadol
Solal-Celigny, Philippe
Boehnke, Axel
Berge, Claude
Genevray, Magali
Zharkov, Artem
Dixon, Mark
Brewster, Michael
Barrett, Martin
MacDonald, David
LANCET HAEMATOLOGY, 2017, 4 (06): : E272 - E282
[27] A MATCH-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY (R-CHEMO) FOR RELAPSED AND/OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
Fox, C.
Arcaini, L.
Hernandez-Ilizaliturri, F.
Tabah, A.
Parker, C.
Jones, J.
Abouzaid, S.
Watkins, C. L.
Bachy, E.
VALUE IN HEALTH, 2019, 22 : S436 - S437
[28] Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2
Liu, Shu
Huang, He
Chen, Rong-xin
Wang, Zhao
Guan, Yan-ping
Peng, Chen
Fang, Xiao-jie
Chen, Zhuo-jia
Guan, Shao-xing
Zhu, Xia
Ren, Quan-guang
Yao, Yu-yi
Huang, Hong-bing
Huang, Min
Wang, Xue-ding
Lin, Tong-yu
ACTA PHARMACOLOGICA SINICA, 2021, 42 (04): : 641 - 647
[29] Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2
Shu Liu
He Huang
Rong-xin Chen
Zhao Wang
Yan-ping Guan
Chen Peng
Xiao-jie Fang
Zhuo-jia Chen
Shao-xing Guan
Xia Zhu
Quan-guang Ren
Yu-yi Yao
Hong-bing Huang
Min Huang
Xue-ding Wang
Tong-yu Lin
Acta Pharmacologica Sinica, 2021, 42 : 641 - 647
[30] CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
Marcus, R
Imrie, K
Belch, A
Cunningham, D
Flores, E
Catalano, J
Solal-Celigny, P
Offner, F
Walewski, J
Raposo, J
Jack, A
Smith, P
BLOOD, 2005, 105 (04) : 1417 - 1423

← 1 2 3 4 5 →